Globe Newswire Dr. Mehdi H. Shishehbor\n\n Mehdi H. Shishehbor, DO, MPH, Ph.D., is appointed Chief Medical Officer of Inquis Medical, a privately held medical device company focused on peripheral vascular innovations. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute ...\n more…
Benzinga U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 50 points on Tuesday. The Dow traded down 0.15% to 32,683.95 while the NASDAQ fell 0.55% to 10,927.54. The S&P 500 also fell, dropping, 0.23% to 3,862.98. Also check this: Investor Optimism Drops Slightly Despite Dow Recording Best Month Since 1976 Leading and Lagging Sectors Energy shares climbed 1% on Tuesday. Leading the sector was strength from YPF Sociedad AnĂ³nima (NYSE: YPF ) and Adams Resources & Energy, Inc. (NYSE: AE ). In trading on Tuesday, consumer discretionary shares fell by 1.1%. Top Headline Eli Lilly and Company (NYSE: LLY ) posted upbeat earnings and sales results for its third quarter on Tuesday, but lowered FY22 adjusted EPS guidance. Eli Lilly reported Q3 sales of $6.94 billion, +2% Y/Y beating the consensus of $6.91 billion. Adjusted EPS increased 12% to $1.98, beating the consensus of $1.92. Eli Lilly lowered FY22 adjusted EPS guidance to $7.70-$7.85 from previous guidance of $7.90-$8.05 and below the consensus of $8.08, reflecting forex impacts. more…
Benzinga U.S. stocks traded lower this morning, with the Dow Jones dropping around 80 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.24% to 32,653.67 while the NASDAQ fell 0.24% to 10,961.44. The S&P 500 also fell, dropping, 0.16% to 3,865.82. Also check this: Investor Optimism Drops Slightly Despite Dow Recording Best Month Since 1976 Leading and Lagging Sectors Energy shares climbed 1.1% on Tuesday. Leading the sector was strength from Global Partners LP (NYSE: GLP ) and Nine Energy Service, Inc. (NYSE: NINE ). In trading on Tuesday, information technology shares fell by 0.7%. Top Headline Pfizer Inc. (NYSE: PFE ) posted upbeat results for its third quarter on Tuesday. Pfizer reported Q3 adjusted EPS of $1.78, up 40% Y/Y, well ahead of the consensus of $1.47. The company achieved revenues of $22.64 billion, down 6%, beating the Wall Street estimate of $21.37 billion. Pfizer revised FY22 sales of $99.5 billion - $102 billion versus the consensus of $99.6 billion and the prior guidance of $98-$102 billion. more…